Fundraising FoxBacked — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Cytosolixcytosolix.cominJun 2023
Cytosolix uses its Tumor Activated Permeability (TAP) platform to redesign small molecule oncology drugs into weakly-acidic derivatives that exploit tumor acidity to selectively target and accumulate in solid tumors while sparing healthy tissue.
AI & Machine LearningBiotechDeep TechTolland, US
John Deacon(Executive Officer, Director)Colin J. Foster(Executive Officer, Director)
BoardJason Whitmire(Director)in
Board seatAlex Brunicki· per SEC Form D
Co-investorsBlueYard CapitalConnecticut Innovations
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.